• Targeting BCL-XL and MCL-1 in Glioblastoma: Insights from BH

  2026-06-03

  The reference study identifies elevated BCL-XL and MCL-1 expression as a key vulnerability in glioblastoma, rendering these tumors highly sensitive to BH3-mimetic–mediated apoptosis. Sequential inhibition of these anti-apoptotic proteins produces robust tumor control in preclinical models, supporting a rational strategy to overcome therapy resistance in GBM and potentially other malignancies.

• AS1842856 Foxo1 Inhibitor: Precision Tool for Gluconeogenesi

  2026-06-02

  AS1842856 Foxo1 Inhibitor enables targeted modulation of gluconeogenesis and autophagy in metabolic disease models, offering high specificity and reproducibility. Its application streamlines workflows investigating Foxo1-mediated gene regulation and supports advanced studies in MSC activation and metabolic dysfunction.

• Improving In Vitro Drug Response Assessment in Cancer Resear

  2026-06-02

  Schwartz's dissertation advances cancer pharmacology by dissecting the distinct roles of growth inhibition and cell death in response to anti-cancer agents. By establishing clear methodologies for quantifying these effects, the study offers researchers refined metrics for evaluating drug efficacy in vitro—paving the way for more precise, predictive preclinical testing.

• MCL-1’s Canonical Anti-Apoptotic Role in Breast Cancer Survi

  2026-06-01

  The reference study by Campbell et al. rigorously demonstrates that breast cancer cell survival and tumor maintenance are critically dependent on the canonical anti-apoptotic function of MCL-1. By combining genetic and pharmacological approaches, the work establishes that targeting MCL-1’s role in apoptosis—rather than its non-apoptotic functions—is key to effective intervention, with direct implications for the use of selective MCL-1 inhibitors in cancer research.

• Stattic STAT3 Inhibitor: Optimizing Cancer Cell Assays

  2026-06-01

  Stattic delivers precise, reproducible STAT3 inhibition for dissecting oncogenic signaling in cancer biology. This article translates cutting-edge research—including the gut microbiome’s role in STAT3-driven cancer progression—into actionable workflows, advanced use-cases, and troubleshooting strategies for head and neck squamous cell carcinoma and beyond.

• CX-5461: RNA Polymerase I Inhibitor Workflows in Cancer Rese

  2026-05-31

  CX-5461 is redefining cancer research as a selective, potent RNA polymerase I inhibitor that enables ribosome biogenesis targeting, autophagy induction, and cellular senescence in solid tumor models. This guide details optimized workflows, troubleshooting strategies, and the latest insights from advanced studies—including combinatorial regimens for overcoming chemoresistance.

• Icatibant in Viral Infections: Insights for Antiviral Resear

  2026-05-30

  The reference study examines the clinical use of icatibant, a bradykinin B2 receptor antagonist, in severe viral infections such as hantavirus (PUUV) and COVID-19. It highlights both the potential benefits and the underlying pathophysiological rationale for targeting the kinin-kallikrein system in these settings, while emphasizing the need for more systematic research to clarify efficacy and timing of intervention.

• Biotin-16-UTP: Protocols and QC for RNA Labeling Workflows

  2026-05-29

  Biotin-16-UTP enables precise incorporation of biotin-labeled uridine into RNA during in vitro transcription, facilitating efficient RNA detection and purification. It is intended strictly for research applications and should not be used in diagnostic or clinical workflows. Proper storage and handling are essential to maintain reagent quality and experimental reliability.

• Levofloxacin (SKU B1959): Reliable Solutions for Cell-Based

  2026-05-29

  This article explores how Levofloxacin (SKU B1959), a synthetic fluoroquinolone antibiotic, addresses common laboratory challenges in cell viability, proliferation, and cytotoxicity assays. Designed for biomedical researchers, it provides evidence-based protocol guidance, discusses workflow reproducibility, and compares vendor reliability for Levofloxacin sourcing.

• Strategic Apoptosis Detection: TUNEL Assays in Translational

  2026-05-28

  This thought-leadership article explores the intersection of mechanistic apoptosis research and translational strategy, highlighting the pivotal role of TUNEL assay-based DNA fragmentation detection. Drawing on recent evidence in spinal cord injury and angiogenesis, it offers actionable protocol guidance and positions the TUNEL Apoptosis Detection Kit (DAB) from APExBIO as a cornerstone for advanced programmed cell death research.

• Tofacitinib Citrate (CP-690550): Advanced Mechanistic Insigh

  2026-05-28

  Explore the precise mechanism and unique endothelial effects of Tofacitinib citrate (CP-690550 citrate), a selective JAK3 inhibitor, in immune regulation research. This article provides an in-depth analysis of cutting-edge findings and practical implications for experimental design.

• ABT-263 (Navitoclax): Enabling Precision Apoptosis Assays

  2026-05-27

  ABT-263 (Navitoclax) empowers researchers to selectively eliminate senescent and apoptosis-resistant cancer cells, advancing caspase-dependent apoptosis research. Its high affinity for Bcl-2 family proteins and proven efficacy in complex cancer models differentiate it as a gold standard for apoptosis assays and senolytic workflows.

• CKI 7 dihydrochloride: Reliable CK1 Inhibition for Cell Assa

  2026-05-27

  CKI 7 dihydrochloride (SKU B4936) is a highly selective Casein kinase 1 inhibitor widely used for dissecting signaling pathways in cancer biology, apoptosis, and circadian rhythm research. This article provides scenario-driven guidance for optimal use, including real-world protocol parameters and evidence-based product selection. Researchers can enhance assay reproducibility and interpretability by leveraging CKI 7 dihydrochloride’s validated performance.

• c-Myc Tag Peptide: Strategic Leverage for Translational Prec

  2026-05-26

  This thought-leadership article dissects the mechanistic and translational value of the c-Myc tag peptide, illuminating how its precision displacement capabilities unlock new experimental control for researchers pursuing transcription factor regulation and cancer biology. Building on contemporary autophagy research and the latest immunoassay innovations, this piece guides translational scientists in deploying the c-Myc tag peptide for rigorous, reproducible discovery.

• Apicidin Disrupts Oocyte Maturation via Meiotic and Epigenet

  2026-05-26

  This study reveals that Apicidin, a natural histone deacetylase inhibitor and emerging mycotoxin, impairs oocyte maturation by disrupting the meiotic apparatus and altering histone acetylation. These findings highlight critical mechanistic links between environmental mycotoxin exposure, epigenetic regulation, and reproductive toxicity, with implications for toxicology screening and epigenetics research.

16247 records 3/1084 page Previous Next 12345 下5页 Last page